16.76MMarket Cap-0.36P/E (TTM)
0.298High0.276Low4.26MVolume0.298Open0.290Pre Close1.20MTurnover9.94%Turnover RatioLossP/E (Static)59.22MShares5.83052wk High0.28P/B12.15MFloat Cap0.24152wk Low--Dividend TTM42.91MShs Float16.220Historical High--Div YieldTTM7.72%Amplitude0.241Historical Low0.281Avg Price1Lot Size
Elevation Oncology Stock Forum
Breakthrough Cancer Drug Shows Promise: First Look at EO-1022 Data for Breast and Lung Cancer
Elevation Oncology Halts Cancer Drug Development, Slashes Jobs in Major Strategic Shift
Benzinga· 2 mins ago
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation --
-- Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigati...
Elevation Oncology to Discontinue Development of Eo-3021; Advancing Eo-1022, While Evaluating Strategic Options
Can Elevation Oncology's $93M War Chest Transform Cancer Treatment? Key Pipeline Updates
No comment yet